Meningococcal disease: treatment and prevention.
Many countries have been experiencing a significant increase in meningococcal disease. With the strains currently circulating, septicaemia is now a more frequent manifestation than meningitis and early recognition of disease manifestations by patient, parent or physician as well as early recognition of disease severity are the most important factors in attempting to reduce mortality and morbidity. Ceftriaxone is the treatment of choice but must be accompanied by aggressive supportive therapy in those with severe disease. The role of steroids is unknown. The evidence to support their use in both meningitis and severe systemic sepsis is discussed. The purified polysaccharide vaccines that have been available for some years may play a limited role in disease prevention. The recently introduced conjugate vaccine for preventing serogroup C disease represents a major advance but no vaccine is currently available to prevent serogroup B disease, cases of which will continue to challenge clinical practice.
Wall
Robert A
RA
Department of Microbiology, Northwick Park Hospital, North West London Hospitals NHS Trust, Watford Road, Harrow, Middlesex, England HA1 3UJ. robert.wall@nwlh.nhs.uk
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy / Q000517:prevention & control; D002443:Ceftriaxone / Q000627:therapeutic use; D003937:Diagnosis, Differential; D006801:Humans; D008585:Meningitis, Meningococcal / Q000188:drug therapy / Q000517:prevention & control; D008589:Meningococcal Infections / Q000517:prevention & control* / Q000628:therapy*; D022401:Meningococcal Vaccines; D013256:Steroids
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D022401:Meningococcal Vaccines; D013256:Steroids; D002443:Ceftriaxone